{"id":62653,"date":"2026-02-16T22:06:03","date_gmt":"2026-02-16T21:06:03","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/"},"modified":"2026-02-16T22:06:03","modified_gmt":"2026-02-16T21:06:03","slug":"poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/","title":{"rendered":"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Gross sales of TWYMEEG<sup>\u00ae<\/sup> in Japan continued to accelerate, increasing by 15.0% in the fourth quarter of 2025 (October\u2013December) compared with the previous quarter, and by 40% compared with the fourth quarter of 2024.<\/b><\/li>\n<li>\n<b>Poxel generated revenue of \u20ac5.0 million for the year ended 31 December 2025 corresponding to 10% royalties on TWYMEEG net sales<\/b><\/li>\n<li>\n<b>As at 31 December 2025, cash and cash equivalents amounted to \u20ac0.9 million.<\/b><\/li>\n<\/ul>\n<p>LYON, France&#8211;(BUSINESS WIRE)&#8211;Regulatory News:<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/5\/POXEL_LOGO_Q.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/21\/POXEL_LOGO_Q.jpg\"><\/a><\/p>\n<p>\n<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxel.com%2F&amp;esheet=54426246&amp;newsitemid=20260216011686&amp;lan=en-US&amp;anchor=POXEL+SA&amp;index=1&amp;md5=1c5e6d0a3cb9cbfbd565e88cb29c04a8\" rel=\"nofollow\" shape=\"rect\">POXEL SA<\/a> (Euronext: POXEL &#8211; FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic disorders, reports today its annual revenue for the fiscal year ended December 31, 2025, and provides an update on its financial position.<\/p>\n<p>\n<b>Consolidated Revenue<\/b><\/p>\n<p>\nPoxel generated consolidated revenue of \u20ac5 millions<sup>1<\/sup> for the year ended 31 December 2025, compared with \u20ac6.6 million in the corresponding period in 2024, which included a milestone payment of \u00a5500 million (\u20ac3.1 million) from Sumitomo following the achievement of a contractual sales threshold for TWYMEEG<sup>\u00ae.<\/sup><\/p>\n<p>\nConsolidated revenue for fiscal year 2025 fully reflects the \u00a5873 million in royalties received from Sumitomo Pharma, namely:<\/p>\n<ul class=\"bwlistcircle\">\n<li>\n10% of TWYMEEG\u00ae net sales in Japan in the first and fourth quarters of 2025, as the \u00a55 billion net sales threshold was exceeded in the last quarter of Sumitomo\u2019s 2024\u20132025 fiscal year, which corresponds to Poxel\u2019s first quarter of 2025, and in the third quarter of Sumitomo\u2019s 2025\u20132026 fiscal year, which corresponds to Poxel\u2019s fourth quarter of 2025.<\/li>\n<li>\n8% of TWYMEEG\u00ae net sales in Japan for Poxel\u2019s second and third quarters of 2025.<\/li>\n<li>\nHowever, the \u00a55 billion threshold was reached during the fourth quarter of 2025, resulting in the retroactive application of the 10% royalty rate to the second and third quarters. Poxel will therefore receive an additional amount of \u00a588 million in respect of the second and third quarters.<\/li>\n<\/ul>\n<p>\nUnder the license agreement with Merck Serono, Poxel will pay Merck Serono a fixed royalty of 8% calculated on net sales of Imeglimine, regardless of the level of sales. In accordance with the royalty monetization agreement with OrbiMed, net positive royalties will be allocated largely to the redemption of the bonds.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40 bwleftsingle bwtopsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<p class=\"bwcellpmargin\">\n<i>EUR (in thousands)<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10 bwtopsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>2025<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q1<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10 bwtopsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>2025<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q2<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10 bwtopsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>2025<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q3<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>2025<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q4<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>3 months<\/b><\/p>\n<\/td>\n<td class=\"bwtopsingle bwsinglebottom bwrightsingle bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>FY<br \/>\n<br \/>2025<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>12 months<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10 bwtopsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>FY<br \/>\n<br \/>2024<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>12 months<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignt bwsinglebottom bwrightsingle bwpadl1 bwwidth40 bwleftsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRoyalty rate<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n10%<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n8%<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n8%<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n10%<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1 bwwidth40 bwleftsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nTWYMEEG<sup>\u00ae <\/sup>Royalties<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>1,060<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>1,021<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>1,047<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>1,403<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>4,532<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n3,184<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1 bwwidth40 bwleftsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nRetroactive royalty adjustments<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>&#8211;<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>235<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>245<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>&#8211;<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>480<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n386<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwpadl1 bwwidth40 bwleftsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nSales-based payment on TWYMEEG<sup>\u00ae<\/sup><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>&#8211;<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>&#8211;<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>&#8211;<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<i>&#8211;<\/i><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n3,066<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwrowaltcolor1 bwpadl1 bwwidth40 bwleftsingle\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total Revenue<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>1,060<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>1,256<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>1,292<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>1,403<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>5,012<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwpadb3 bwalignc bwvertalignm bwrowaltcolor1 bwpadl1 bwwidth10\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>6,636<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>TWYMEEG<sup>\u00ae <\/sup>(Imeglimin)<\/b><\/p>\n<ul class=\"bwlistdisc\">\n<li>\nFor the quarter ended December 2025, gross sales of TWYMEEG\u00ae in Japan increased by 15% to \u00a52.9 billion (\u20ac1.4 million\u00b9), compared with sales of \u00a52.5 billion in the previous quarter, as reported by Sumitomo Pharma.<\/li>\n<li>\nPoxel continues to implement its recovery plan and expects to receive double-digit royalty growth on TWYMEEG\u00ae sales in 2026.<\/li>\n<\/ul>\n<p>\n<b>Consolidated cash and cash equivalents<\/b><\/p>\n<p>\nAs at 31 December 2025, total consolidated cash and cash equivalents amounted to \u20ac0.9 million, compared with \u20ac0.6 million as at 30 September 2025.<\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb bwblockalignl bwwidth100\">\n<tr>\n<td class=\"bwrightsingle bwsinglebottom bwwidth52 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<i>EUR (in thousands)<\/i><\/p>\n<\/td>\n<td class=\"bwvertalignb bwtopsingle bwsinglebottom bwrightsingle bwwidth24 bwpadl1 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q4 2025<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignb bwsinglebottom bwwidth24 bwpadl1 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwalignc bwcellpmargin\">\n<b>Q4 2024<\/b><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwrightsingle bwsinglebottom bwwidth52 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwvertalignb bwpadb3 bwwidth24 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n866<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth24 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n3,657<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwvertalignb bwrightsingle bwsinglebottom bwwidth52 bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\nCash equivalents<\/p>\n<\/td>\n<td class=\"bwrightsingle bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth24 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;<\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth24 bwalignc bwpadl1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n&#8211;<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom bwrightsingle bwwidth52 bwpadl1 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n<b>Total cash and cash equivalents<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwrightsingle bwpadr0 bwvertalignb bwpadb3 bwwidth24 bwalignc bwpadl1 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>866<\/b><\/p>\n<\/td>\n<td class=\"bwsinglebottom bwpadr0 bwvertalignb bwpadb3 bwwidth24 bwalignc bwpadl1 bwrowaltcolor1\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n<b>3,657<\/b><\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Post-closing events<\/b><\/p>\n<p>\n<b>Approval of the continuation plan and conclusion of the judicial reorganisation proceedings<\/b><\/p>\n<p>\nThe continuation plan of Poxel was approved by the Lyon Commercial Court on 22 January 2026. This decision brings to an end the observation period opened on 5 August 2025 and confirms Poxel SA\u2019s exit from judicial reorganisation proceedings. It enables the Company to implement the continuation plan presented to shareholders in several communications in November and December 2025, including the capital increases approved by the General Meeting of 11 December 2025, which will be the subject of specific press releases.<\/p>\n<p>\n<b>About Poxel SA<\/b><\/p>\n<p>\nPoxel is a <b>clinical stage biopharmaceutical Company<\/b> developing <b>innovative treatments<\/b> <b>for chronic serious diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH)<\/b> and rare disorders. For the treatment of MASH, <b>PXL065<\/b> (deuterium-stabilised Rpioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of <b>PXL770<\/b>, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). <b>TWYMEEG<sup>\u00ae<\/sup><\/b> (Imeglimin), Poxel\u2019s first-in-class product that targets mitochondrial dysfunction, is now marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and 5 sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.<\/p>\n<p>\nFor more information, please visit: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.poxelpharma.com&amp;esheet=54426246&amp;newsitemid=20260216011686&amp;lan=en-US&amp;anchor=www.poxelpharma.com&amp;index=2&amp;md5=b8720311bc1891db8c86fa4a6ca070b2\" rel=\"nofollow\" shape=\"rect\">www.poxelpharma.com<\/a><\/p>\n<p>\nAll statements other than statements of historical fact included in this press release concerning future events are subject to (i) change without notice and (ii) factors beyond the Company&#8217;s control. These statements may include, but are not limited to, any statements preceded by, followed by, or including words such as \u2018objective,\u2019 \u2018believe,\u2019 \u2018expect,\u2019 \u2018aim,\u2019 \u2018intend,\u2019 \u2018may,\u2019 \u2018anticipate,\u2019 \u2018estimate,\u2019 \u2018plan,\u2019 \u2018project,\u2019 \u2018will,\u2019 \u2018could,\u2019 \u2018likely,\u2019 \u2018should,\u2019 and other words and terms of similar meaning, or the negative form of these words and terms. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company&#8217;s control that could cause the Company&#8217;s actual results or performance to differ materially from the results or performance expected, expressed or implied in such forward-looking statements. Actual events or results may differ from those described in this document due to a number of risks or uncertainties described in the Company&#8217;s 2024 Universal Registration Document available on the Company&#8217;s website and that of the AMF (<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.amf-france.org%2Ffr&amp;esheet=54426246&amp;newsitemid=20260216011686&amp;lan=en-US&amp;anchor=https%3A%2F%2Fwww.amf-france.org%2Ffr&amp;index=3&amp;md5=5a9d4e1e1f5c6022aeffbb8339807dca\" rel=\"nofollow\" shape=\"rect\">https:\/\/www.amf-france.org\/fr<\/a>). The Company does not endorse and is not responsible for the content of external hyperlinks mentioned in this press release.<\/p>\n<p class=\"bwalignc\">\n<b>Glossary<\/b><\/p>\n<p>\nFor the sake of clarity and transparency, please find below a list of words and\/or expressions used in this press release or in other communications from Poxel:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Sumitomo Pharma\u2019s financial year<\/b> runs from April to March. By way of example, fiscal year 2025 runs from April 1, 2025 to March 31, 2025.<\/li>\n<li>\n<b>TWYMEEG royalties<\/b>: In accordance with the agreement with Sumitomo Pharma, Poxel is eligible to receive royalties on sales of TWYMEEG (Imeglimin) in Japan.<\/p>\n<ul class=\"bwlistcircle\">\n<li>\nSumitomo Pharma reports the number of gross sales of TWYMEEG, while royalties on TWYMEEG sales are calculated based on net sales;<\/li>\n<li>\nNet sales represent gross sales fewer potential rebates, allowances and costs such as prepaid freight, shipping and handling charges, customs duties and insurance costs;<\/li>\n<li>\nPoxel is eligible for tiered royalties ranging from 8% to 18% on Sumitomo Pharma\u2019s net sales of TWYMEEG.<\/li>\n<\/ul>\n<\/li>\n<li>\n<b>Positive net royalties<\/b>: In accordance with the license agreement with Merck Serono, Poxel will pay Merck a fixed percentage of 8% of net sales of TWYMEEG, regardless of the level of sales. Royalties on TWYMEEG net sales received by Poxel above this 8% threshold are referred to as positive net royalties. Accordingly, net royalties will be positive for Poxel when TWYMEEG net sales exceed \u00a55 billion during a fiscal year, and the royalty rate reaches 10% or more.<\/li>\n<li>\n<b>Poxel<\/b> refers to the Poxel Group, including its subsidiaries (Poxel Inc. and Poxel KK), as well as the three secured trusts established as part of the royalty monetization and debt restructuring transactions announced on September 30, 2025.<\/li>\n<\/ul>\n<p>\n<sup>1<\/sup> <i>Converted at the exchange rate as at 31 December 2025<\/i><\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Investor relations \/ Media <\/b><\/p>\n<p>\nNewCap<br \/>\n<br \/>Th\u00e9o Martin \/ Paul Boivin<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;t&#x6f;:&#105;&#x6e;&#118;&#x65;&#115;&#x74;o&#x72;s&#64;&#x70;&#111;&#x78;e&#x6c;p&#x68;&#x61;&#114;&#x6d;&#97;&#x2e;c&#x6f;m\" rel=\"nofollow\" shape=\"rect\">&#x69;n&#x76;&#101;s&#x74;&#111;&#x72;&#x73;&#64;&#x70;&#111;x&#x65;&#108;&#x70;&#104;a&#x72;&#109;a&#x2e;&#99;&#x6f;&#109;<\/a><br \/>+33 1 44 71 94 94<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Gross sales of TWYMEEG\u00ae in Japan continued to accelerate, increasing by 15.0% in the fourth quarter of 2025 (October\u2013December) compared with the previous quarter, and by 40% compared with the fourth quarter of 2024. Poxel generated revenue of \u20ac5.0 million for the year ended 31 December 2025 corresponding to 10% royalties on TWYMEEG net sales &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62653","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Gross sales of TWYMEEG\u00ae in Japan continued to accelerate, increasing by 15.0% in the fourth quarter of 2025 (October\u2013December) compared with the previous quarter, and by 40% compared with the fourth quarter of 2024. Poxel generated revenue of \u20ac5.0 million for the year ended 31 December 2025 corresponding to 10% royalties on TWYMEEG net sales ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-16T21:06:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position\",\"datePublished\":\"2026-02-16T21:06:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/\"},\"wordCount\":1155,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260216011686\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/\",\"name\":\"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260216011686\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"datePublished\":\"2026-02-16T21:06:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260216011686\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260216011686\\\/en\\\/729490\\\/22\\\/POXEL_LOGO_Q.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/","og_locale":"en_US","og_type":"article","og_title":"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Pharma Trend","og_description":"Gross sales of TWYMEEG\u00ae in Japan continued to accelerate, increasing by 15.0% in the fourth quarter of 2025 (October\u2013December) compared with the previous quarter, and by 40% compared with the fourth quarter of 2024. Poxel generated revenue of \u20ac5.0 million for the year ended 31 December 2025 corresponding to 10% royalties on TWYMEEG net sales ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/","og_site_name":"Pharma Trend","article_published_time":"2026-02-16T21:06:03+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position","datePublished":"2026-02-16T21:06:03+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/"},"wordCount":1155,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/","url":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/","name":"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg","datePublished":"2026-02-16T21:06:03+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260216011686\/en\/729490\/22\/POXEL_LOGO_Q.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/poxel-reports-its-2025-revenue-and-provides-an-update-on-its-financial-position\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Poxel Reports its 2025 Revenue and Provides an Update on its Financial Position"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62653","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62653"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62653\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62653"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62653"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62653"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}